drugset / Trial / NCT06181526
Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis
RandomizedSequentialDouble-blindTreatment
Summary
This study is a single-center, randomized, double-blind, placebo parallel-controlled, dose-escalation clinical study. The aim of this study was to evaluate the safety, tolerability, and preliminary effect of Aleeto in adult patients with ALS, and to provide an appropriate dose for the future clinical trial.
Timeline
- Start
- 2023-12-15
- Primary completion
- 2024-10-30
- Completion
- 2024-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aleeto | Protein / enzyme biologic | 0.5 ug/kg | Intrathecal |
| Subject | Aleeto | Protein / enzyme biologic | 1 ug/kg | Intrathecal |
| Subject | Aleeto | Protein / enzyme biologic | 2 ug/kg | Intrathecal |